Who is involved?
This study is led by
Professors Paul Little
from the University of Southampton and
Theo Verheij
from Utrecht. Paul is internationally known for both trials leadership and for developing clinical prediction rules, and recently led the large GRACE trial of amoxicillin for LRTI in adults (n=2061) and gained funding as Principal Investigator of the PRIME Programme for the 3C cohort of adults and children (currently n=30,000).
Theo has led numerous observational and intervention studies on respiratory tract infections in primary care and antibiotic use and is involved in both national and international guidelines on respiratory infections.
Recruitment in full flow in Primary care sites working with the University of Southampton, University of Bristol and Cardiff University
The collaborators are international leaders in respiratory infection research, including paediatric respiratory research, and additionally have paediatric trials expertise.
The study will be supported by Dr Gillian O'Reilly as project manager in Southampton, Dr Nick Francis in Cardiff and Professor Alastair Hay in Bristol together with their coordinators and administrators.
NIHR Portfolio adoption
The study is adopted onto the NIHR Portfolio so Service Support Costs are payable.
Reimbursement
Most of the reimbursement will come from Research Costs payable quarterly in arrears for activity undertaken. Service Support Costs (SSCs) will pay for consent as this is considered a safety requirement. If all Clinical Research Networks (CRNs) agree the SSC from Wessex as lead the total amount that could be reimbursed will be of the order of £140 per child recruited into the trial and £100 per child recruited into the study.
If you would like any further information please contact the project manager
Dr Gillian O'Reilly
at the University of Southampton at
artic-pc@soton.ac.uk
thank you.
Many thanks for your time.